Cargando…

JAK Inhibitors: Treatment Efficacy and Safety Profile in Patients with Psoriasis

Janus kinase (JAK) pathways are key mediators in the immunopathogenesis of psoriasis. Psoriasis treatment has evolved with the advent of targeted therapies, which inhibit specific components of the psoriasis proinflammatory cascade. JAK inhibitors have been studied in early phase trials for psoriasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Leeyen, Armstrong, April W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027021/ https://www.ncbi.nlm.nih.gov/pubmed/24883332 http://dx.doi.org/10.1155/2014/283617

Ejemplares similares

Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
por: Kvist-Hansen, Amanda, et al.
Publicado: (2019)

Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis
por: Sarabia, Samantha, et al.
Publicado: (2022)

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
por: Mease, Philip J., et al.
Publicado: (2014)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease
por: Fries, Walter, et al.
Publicado: (2023)

Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy
por: Brezinski, Elizabeth A., et al.
Publicado: (2012)

Calcipotriol/betamethasone for the treatment of psoriasis: efficacy, safety, and patient acceptability
por: Rogalski, Christina
Publicado: (2015)

Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability
por: Abrouk, Michael, et al.
Publicado: (2016)

The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis
por: Jenneck, Claudia, et al.
Publicado: (2007)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review
por: AMIRI, Diva, et al.
Publicado: (2023)

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability
por: Farahnik, Benjamin, et al.
Publicado: (2016)

A Clinician’s Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis
por: Armstrong, April W., et al.
Publicado: (2016)

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

Managing Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care Practitioners
por: Armstrong, April W., et al.
Publicado: (2015)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
por: Halle, Briana Rose, et al.
Publicado: (2021)

Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
por: Wei, Dongfan, et al.
Publicado: (2023)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Safety of selective IL‐23p19 inhibitors for the treatment of psoriasis
por: Crowley, J.J., et al.
Publicado: (2019)

Waiting for JAK inhibitor safety data
por: Kragstrup, Tue Wenzel, et al.
Publicado: (2022)

A systematic review on the efficacy and safety of Infliximab in patients with psoriasis
por: Wang, Jin, et al.
Publicado: (2015)

Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review
por: Emery, Paul, et al.
Publicado: (2018)

Beyond Methotrexate and Biologics in RA – Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium
por: Chatzidionysiou, Katerina
Publicado: (2020)

Efficacy of JAK inhibitors in Crohn’s Disease
por: Rogler, Gerhard
Publicado: (2020)

Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis
por: Morelli, Martina, et al.
Publicado: (2018)

Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials
por: Kang, Qin, et al.
Publicado: (2022)

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
por: Merola, Joseph F., et al.
Publicado: (2022)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation Survey
por: Armstrong, April, et al.
Publicado: (2022)

Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021)

Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011
por: Armstrong, April W., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_po0ds4i1thnmta7qk658bn7rne